Evidence map›Paper›PMID 29563589›Full record

Trial reportBone marrow transplantation2018

Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD.

Jacob Rozmus, Sabine Ivison, Amina Kariminia, Vivian M Leung, Susanna Sung, Peter Subrt, Stephanie J Lee, Eric Boilard, Irwin Walker, Ronan Foley and 4 more

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jacob Rozmus *Michael Cuccione Childhood Cancer Research Program, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
Sabine Ivison *CFRI, University of British Columbia, Vancouver, BC, Canada.
Amina KariminiaMichael Cuccione Childhood Cancer Research Program, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
Vivian M LeungMichael Cuccione Childhood Cancer Research Program, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
Susanna SungMichael Cuccione Childhood Cancer Research Program, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
Peter SubrtMichael Cuccione Childhood Cancer Research Program, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
Stephanie J LeeFred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
Eric BoilardCentre Hospitalier de l'Université Laval, Quebec City, QC, Canada.
Irwin WalkerHamilton Health Sciences and McMaster University, Hamilton, ON, Canada.
Ronan FoleyHamilton Health Sciences and McMaster University, Hamilton, ON, Canada.
Jeff LiptonPrincess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada.
Geneviève GallagherCHU de Quebec, Hopital Enfant-Jesus, Quebec City, QC, Canada.
Stephen CoubanCapital District Health Authority and Dalhousie University, Halifax, NB, Canada.
Kirk R SchultzMichael Cuccione Childhood Cancer Research Program, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada. kschultz@mail.ubc.ca.ORCID http://orcid.org/0000-0002-0001-6438

Funding

Training and Career Development CoreU54CA163438 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2011 to 2014
$3.7M
Transplantation of G-CSF Stimulated Marrow vs BloodR01CA108752 · NCI · UNIVERSITY OF BRITISH COLUMBIA · PI SCHULTZ, KIRK R · 2006 to 2011
$2.4M
CIHRNCI NIH HHS R01 CA108752NCI NIH HHS U54 CA163438
6 · The paper itself

Abstract

Toll-like receptor-9 (TLR9) responsive B cells have previously been associated with the onset of extensive chronic graft-versus-host disease (cGvHD). We hypothesized that the onset of cGvHD associated with a higher level of plasma-free mitochondrial DNA (mtDNA), a putative TLR9 agonist. Plasma cell-free mtDNA levels were measured in 39 adult patients post-HSCT with and without cGvHD. mtDNA was isolated from plasma and quantified by Q-PCR amplification. We correlated B cell responsiveness to CpG-DNA, a prototypical TLR9 agonist, and previously identified cGVHD biomarkers with mtDNA levels. Free plasma mtDNA were elevated in patients post-HSCT without cGvHD compared to normal non-HSCT adults. There was a significantly higher level of free plasma mtDNA associated with the onset of cGvHD (3080 ± 1586 versus 1834 ± 1435 copies/μL; p = 0.02) compared to 6 months post-HSCT controls. Free mtDNA levels post-HSCT correlated with B cell responsiveness to CpG-DNA and known cGvHD biomarkers: CXCL10 (p = 0.003), ICAM-1 (p = 0.007), CXCL9 (p = 0.03), sCD25 (p = 0.05) and sBAFF (p = 0.05), and percentage of CD21

Indexed as

AdolescentAdultAllograftsBiomarkersB-LymphocytesCell-Free Nucleic AcidsChronic DiseaseDNA, MitochondrialFemaleGraft vs Host DiseaseHematologic NeoplasmsHumansMaleMiddle AgedToll-Like Receptor 9BiomarkersCell-Free Nucleic AcidsDNA, MitochondrialTLR9 protein, humanToll-Like Receptor 9

Identifiers

PMID29563589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.